[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100471888":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":24,"responsibleParty":45,"collaborators":7,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":7,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":7,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"DBV Technologies","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"COMBINATION_PRODUCT","DBV712 250 mcg","Daily epicutaneous delivery.",[14],"Viaskin® Peanut",[16,22],{"name":17,"role":18,"phone":19,"phoneExt":20,"email":21},"Anne B Cropp, Pharm. D.","CONTACT","1-888-441-793","125","DBV712.eap@earlyaccesscare.com",{"name":23,"role":18,"phone":19,"phoneExt":20,"email":21},"Laurie Reynolds, BS",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Early Access Care, LLC","AVAILABLE","Madison","Connecticut","06443","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-72.59843,41.27954,{"lat":37,"lon":36},[40,42],{"name":17,"role":18,"phone":41,"phoneExt":20,"email":21},"888-441-7938",{"name":43,"role":18,"phone":44,"phoneExt":20,"email":21},"Laurie Reynolds, 06443","1-888-441-7938",{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100471888","expanded-access-protocol-of-viaskin-peanut-dbv712-in-peanut-allergic-children-100471888",false,"NCT05424731","Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children","Viaskin® Peanut (DBV712) Compassionate Use in Peanut-allergic Children Previously Enrolled in a DBV712 Clinical Study","Inclusion Criteria:\n\n* Participation is by invitation, limited to individuals completing clinical study V712-303 (PEOPLE), previous Expanded Access Program or a DBV clinical study initiated after 31-Jan-2022\n* Male and females; ages ≥ 2 years old at Visit 1 or current or prior studies.\n* Negative urine pregnancy test for female participants of childbearing potential.\n\nExclusion Criteria:\n\n* Early withdrawal from a DBV712 clinical study.\n* History of non-compliance during the primary clinical study or unable to follow the protocol requirements.\n* Generalized dermatologic disease extending widely on the skin.\n* History of intolerance or who developed hypersensitivity to excipients of the DBV712 patches.","ALL","2 Years","17 Years","EXPANDED_ACCESS","This is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.",[60],"Peanut Allergy",[62,63,64,65],"EPIT","Epicutaneous","Immunotherapy","Viaskin","2026-01-14",{"date":68,"type":69},"2026-01-15","ACTUAL",{"name":5,"class":6},1]